Why the study?
Does a prototype inactivated hepatitis A virus vaccine elicit antibodies and protect against HAV challenge in animal models?
Population
BS-C-1 cells, guinea pigs, and owl monkeys
Design
Preclinical
Authors
Loading...
Does not alter human vaccination practice; extends preclinical protection data for inactivated HAV vaccines.
Does a prototype inactivated hepatitis A virus vaccine elicit antibodies and protect against HAV challenge in animal models?
A prototype inactivated whole virus hepatitis A vaccine prepared from cell culture is immunogenic and protects owl monkeys against virulent HAV challenge.
Binn et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: